A61P 17 - Drugs for dermatological disorders

Patents for A61P 17 - Drugs for dermatological disorders (106,455)
11/2002
11/14/2002	US20020169176 Method for inhibiting retinoid skin damage
11/14/2002	US20020169164 Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases
11/14/2002	US20020169159 An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor
11/14/2002	US20020169150 Hormone replacement therapy
11/14/2002	US20020169144 Angiogenesis inhibition
11/14/2002	US20020169133 Treatment of diseases characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to symptoms of fibrosis
11/14/2002	US20020169105 Use of active enamel substances as wound healing, anti-bacterial and/or anti-inflammatory agents
11/14/2002	US20020168763 Isolated homozygous stem cells, differentiated cells derived therefrom, and materials and methods for making and using same
11/14/2002	US20020168754 Nucleotide sequences coding polypeptides for use in the treatment of gastric, testicular, retinal, nervous system and immunological disorders
11/14/2002	US20020168740 Kinase for use in the treatment of inflammation, viral infection, cancer, sepsis, psoriasis and restenosis
11/14/2002	US20020168716 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of tumors, immunological, autoimmune, skin, viral, bone, nervous system and inflammatory disorders
11/14/2002	US20020168710 Anticancer agents; cardiovascular disorders; anticholesterol agents
11/14/2002	US20020168415 Biocompatible; culture product; anticancer agents
11/14/2002	US20020168389 Oil in water emulsion; skin disorders
11/14/2002	US20020168388 Topical cosmetic composition
11/14/2002	US20020168358 Modulating the binding of the particular chemokines SLC (secondary lymphoid chemokine), and MIP-3b (macrophage inflammatory protein-3b), to immune system T-cells and dendritic cells to treat adverse inflammatory responses etc
11/14/2002	US20020168327 Use of lipophilic agent or lipid precursor and/or promoter for treating and/or preventing dandruff by strengthening scalp
11/14/2002	US20020168325 Administering inhibitor of nitric oxide synthase
11/14/2002	CA2827671A1 Phosphorus-containing antimicrobial compounds and methods for their use
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2452245A1 Recombinant fusion proteins and the trimers thereof
11/14/2002	CA2446946A1 Gene transfer of angiogenic factor for skin disease
11/14/2002	CA2446926A1 Dermatological formulations
11/14/2002	CA2446795A1 Sulfamide, sulfamate, sulfonamide, urea, amide, alpha, alpha-difluoro amide oxalyl diamide, and heterobicycles fkbp-binding ligands
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446120A1 Novel arylheteroalkylamine derivatives
11/14/2002	CA2445679A1 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	CA2445634A1 Acne treatment comprising lipoxygenase inhibitors
11/14/2002	CA2445381A1 Phosphorous containing antimicrobial compounds and methods for their use
11/14/2002	CA2435142A1 Kinases and phosphatases
11/13/2002	EP1256582A1 1h-imidazopyridine derivatives
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256346A1 Remedies for external use for allergic skin diseases
11/13/2002	EP1256336A2 Two-phase gel composition
11/13/2002	EP1255845A2 Modified cytokines for use in cancer therapy
11/13/2002	EP1255829A2 Inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
11/13/2002	EP1255827A2 Novel oligonucleotides and use of oligonucleotides modulating the expression of enzymes involved in the synthesis of melanic pigments, as depigmentation agents
11/13/2002	EP1255764A1 Purine derivatives
11/13/2002	EP1255763A2 Motilide compounds
11/13/2002	EP1255756A1 Saccharin derivatives as orally active elastase inhibitors
11/13/2002	EP1255752A2 Pyrrole substituted 2-indolinone protein kinase inhibitors
11/13/2002	EP1255751A2 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors
11/13/2002	EP1255732A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
11/13/2002	EP1255726A2 (r)-2-aryl-propionamides, useful in the inhibition of il-8 induced chemiotaxis of neutrophils
11/13/2002	EP1255725A2 5-aminolevulinic acid formulation dissolved/dispersed in non-aqueous solvents
11/13/2002	EP1255551A1 Use of paullone derivatives for making medicines
11/13/2002	EP1255543A2 Use of retinoid-type compounds as antibacterial agents
11/13/2002	EP1255530A2 Cosmetic or medicinal composition containing sesquiterpene lactone or the like for treating hair-growth related disorders, and preparation method
11/13/2002	EP1255456A1 Use of glutamate and/or a glutamate precursor for the preparation of a nutritional or pharmaceutical preparation for the treatment or prevention of hyperpermeability or undesired permeability of the intestinal wall
11/13/2002	EP1056451B1 Bicyclic pyrrole derivatives as mcp-1 inhibitors
11/13/2002	EP0738281B1 Peptides and their uses against psoriasis
11/13/2002	CN1379814A Embryonic or stem-like cell lines produced by cross species nuclear transpcantation and methods for enhancing mebryonic development by genetic alteration of donor cells or by tissue culture conditions
11/13/2002	CN1379772A Substituted indoles for modulating NFKB activity
11/13/2002	CN1379763A Pyrazoloanthrone and derivatives thereof as JNK inhibitors and their compositions
11/13/2002	CN1379762A Beta substituted metalloprotease inhibitors
11/13/2002	CN1379685A Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta integrins
11/13/2002	CN1379681A therapeutic angiogenic factors and methods for their use
11/13/2002	CN1379675A 24-hydroxyvitamin D, analogs and use thereof
11/13/2002	CN1379669A Valdecoxib compositions
11/13/2002	CN1379668A 3(5)-ureido-pyrazole derivatives, process for their preparation and their use as antitumor agents
11/13/2002	CN1379623A Topical, non-cytotoxic, antimicrobial hydrogel with thixotropic properties
11/13/2002	CN1378852A Detoxicating ointment for treating burn and scald and its preparing process
11/13/2002	CN1378851A Powdered black Chinese medicine for treating burn and scald and its preparing process
11/13/2002	CN1378842A Ointment for treating dermatopathy
11/13/2002	CN1378839A 'Runlizi' tablet
11/12/2002	US6479633 Chemokine alpha 2
11/12/2002	US6479544 Therapeutic combinations of fatty acids
11/12/2002	US6479538 Cyclic ether vitamin D3 compounds, 1α(OH)3-EPI-vitamin D3 compounds and uses thereof
11/12/2002	US6479527 Bicyclic pyrrole derivatives as MCP-1 inhibitors
11/12/2002	US6479516 4-arylpiperidine derivatives for the treatment of pruritus
11/12/2002	US6479513 Anticancer compound and enantiomer separation method useful for synthesizing said compound
11/12/2002	US6479512 Tyrosine kinase inhibitors
11/12/2002	US6479505 6-arylphenanthridines with PDE-IV inhibiting activity
11/12/2002	US6479502 Hydroxamic acid derivatives as proteinase inhibitors
11/12/2002	US6479492 Compounds which inhibit leukocyte adhesion mediated by VLA-4
11/12/2002	US6479490 Treatment of diseases characterized by excess th2 cytokines and/ or an excess ige production.
11/12/2002	US6479460 Pseudopeptidic osteogenic growth polypeptide
11/12/2002	US6479283 Stimulation, culture and preservation of pancreatic cells
11/12/2002	US6479060 Elegant hydrogenated castor oil ointments
11/12/2002	US6479052 Spray delivery of cells
11/12/2002	CA2249458C Antipsoriatic compositions, method of making, and method of using
11/12/2002	CA2110162C Pharmaceutical compositions containing 4-substituted imidazoles to be administered transdermally
11/12/2002	CA2059558C Use of calcium antagonists for treating scars
11/12/2002	CA2055963C Chimeric fibroblast growth factor
11/12/2002	CA2009533C Novel cyclosporin galenic forms
11/11/2002	CA2385692A1 Thiazole derivatives
11/11/2002	CA2347879A1 Substituted dicinnamoylquinides and their use in augmentation of adenosine function
11/07/2002	WO2002088664A2 Control of compactability through crystallization
11/07/2002	WO2002088354A1 The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
11/07/2002	WO2002088348A2 Lipid producing cells and uses thereof
11/07/2002	WO2002088317A2 Fusion molecules and methods for treatment of immune diseases
11/07/2002	WO2002088316A2 G-protein coupled receptors
11/07/2002	WO2002088181A2 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
11/07/2002	WO2002088180A2 Use of alpha 1-antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic or arterial wounds
11/07/2002	WO2002088167A1 Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
11/07/2002	WO2002088138A1 Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
11/07/2002	WO2002088137A1 Pkb-3564 substance with neovascularization inhibitory activity
11/07/2002	WO2002088115A1 Novel sulfonamide derivatives, intermediate thereof, its preparation methods, and pharmaceutical composition comprising the same
11/07/2002	WO2002088111A1 Novel benzylpiperidine compound

1 ... 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 ... 1065